Clinical trials: Anaplastic Thyroid Carcinoma
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Carcinoma, Anaplastic
Taiwanese Anaplastic Thyroid Cancer Registry
Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy.
- Trial name
- TATC (NCT07138261)
- Where
- 9 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Health Research Institutes, Taiwan
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals
Anaplastic Thyroid Cancer
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer.
- Trial name
- NCT06374602
- Testing
- Pembrolizumab + Lenvatinib
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Anaplastic Thyroid Cancers
A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance…
- Trial name
- TAM-RT (NCT02516774)
- Testing
- Adalimumab
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Head and Neck Cancer
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or…
- Trial name
- NCT00095836
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer.
- Conditions
- BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT03975231
- Testing
- Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Trial name
- NCT00625846
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)